The translation of stem cell therapies begins with a well-characterized and thoroughly documented starting cell source. REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer cell therapy developers streamlined starting material that provides a gateway into early-stage clinical development. By combining regulatory alignment with ethical sourcing and footprint-free mRNA reprogramming, REPROCELL now offers various male and female, ready-to-use, clinical-grade iPSC lines manufactured in our facilities, in the U.S. and Japan.
Ethical Donor Recruitment & Regulatory Alignment
REPROCELL sources healthy donors, with cell collections being made in the U.S. with IRB-approved informed consent. Donor eligibility screening follows FDA 21 CFR 1271, EMA Directive 2006/17/EC, and PMDA Notification No. 375 guidelines. Find full details in our Clinical Stem Cell Services FAQ.
High-integrity Reprogramming with Our StemRNA™ Technology
The heart of the process is REPROCELL’s proprietary non-integrating StemRNA™ clinical reprogramming technology. Footprint- and virus-free, StemRNA ensures safety by eliminating genomic vector retention, which is crucial for clinical applications. StemRNA also offers faster, more stable induction of pluripotency.
Comprehensive QC
Clinical iPSC Seed stock Clones undergo rigorous quality control (QC) characterization, including:
- Viability & Growth Rate
- Sterility/Mycoplasma/Endotoxin tests
- Genomic profiling (HLA/KIR, WGS, G-banded karyotyping, OncoPanel Analyses)
- Flow Cytometry for Key Pluripotency Markers
- ICC for Pluripotency Markers
- Tri-lineage Differentiation Assays
Off-the-shelf, Globally Sourced Clinical iPSC lines
For cell therapy developers accelerating preclinical exploration, REPROCELL offers 16 male and female ready-to-use clinical-grade iPSC lines from five healthy donors generated at our U.S. and Japan facilities. Our available donors span age groups and represent various blood groups. Selected clones can be further expanded in a GMP environment to Master Cell Banks (MCBs) at our USA GMP facility or at our CDMO partner in Europe- Histocell.
Just launched!
Spotlight: Our Latest Off-the-Shelf Male Clinical iPSC Lines
We generated multiple clones from 23- and 27-year-old, Caucasian, healthy male donors, both with blood type A+.
- iPSC clones exhibit a normal 46XY karyotype, as certified by G-band analysis.
- Flow cytometry confirms stable expression and purity of OCT3/4, SSEA-4.
- Real-time PCR data demonstrate robust trilineage differentiation potential, strong expression of germ layer genes (Pax6, MAP2, Brachyury, GATA4, Sox17, FoxA2) post-differentiation.
- STR genotyping ensures identity and purity across the manufacturing process.
HLA A & HLA DPA1 Homozygous female iPSC Line
Another of our recent clinical-grade iPSC lines, derived from a healthy 22-year-old Caucasian female donor (O+ blood type), is homozygous at HLA A and HLA DPA1. This markedly enhances the matching potential for recipients and expands its clinical utility. Multiple clones are available from this donor with specific targeted differentiation data for therapy-relevant cell types, allowing developers options in clone selection.
Why choose REPROCELL’s StemRNA™ iPSC Seed Stocks?
- Regulatory-grade assurance: Footprint-free reprogramming, compliant with FDA/EMA/PMDA.
- Proven quality: Multi-modal QC confirming genomic integrity, pluripotency, and differentiation capacity.
- Commercial freedom: A single one-time royalty grants full commercial and therapeutic rights—no milestones, no surprises.
- Flexible sourcing: Donors, recruited in the U.S. & Japan
Conclusion
In summary, REPROCELL’s StemRNA™ Clinical iPSC Seed Stock Clones offer a reliable, regulatory-compliant route for developers to source high-quality iPSCs—backed by robust data and global manufacturing infrastructure. Find out more on our website: GMP iPSC Production Service: Clinical-grade Human iPSCs and GMP MCBs.